Valuation: Scancell Holdings plc

Market Cap 12Cr 16Cr 14Cr 13Cr 22Cr 1.5TCr 22Cr 148.84Cr 58Cr 750.97Cr 59Cr 58Cr 2.5TCr P/E 2026 *
-6.38x
P/E 2027 * -12.1x
Enterprise Value 13Cr 17Cr 15Cr 14Cr 24Cr 1.63TCr 24Cr 162.25Cr 64Cr 818.61Cr 64Cr 63Cr 2.72TCr EV / Sales 2026 *
101x
EV / Sales 2027 * 54.8x
Free-Float
96.87%
Yield 2026 *
-
Yield 2027 * -
1 day+0.63%
Current month-1.54%
1 month-28.89%
3 months-61.60%
6 months-26.30%
Current year-3.03%
1 week 9.5
Extreme 9.5
9.7
1 month 9.3
Extreme 9.3
14
Current year 9.3
Extreme 9.3
29.5
1 year 7.86
Extreme 7.8555
29.5
3 years 7.26
Extreme 7.26
29.5
5 years 7.26
Extreme 7.26
29.5
10 years 0.11
Extreme 0.1118
29.5
Manager TitleAgeSince
Chief Executive Officer 69 28/07/2021
Chief Executive Officer 64 18/11/2024
Director of Finance/CFO 50 24/04/2026
Director TitleAgeSince
Director/Board Member 69 17/11/2010
Director/Board Member 74 23/10/2019
Director/Board Member 64 24/09/2020
Date Insider Type Main position Quantity % Market Cap.
16/09/25
Vulpes Investment Management Pte Ltd.
BuyCompany 31,50,000 0.3038%
08/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 1,02,236 0.0099%
04/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 44,00,000 0.4244%
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%0.00%-8.57%-8.57% 16Cr
-0.09%-1.63%+1.84%+19.94% 4.88TCr
+4.07%+2.43%+483.70%+623.80% 4.54TCr
+4.33%+0.98%+12.80%+88.53% 4.12TCr
+1.94%-0.31%+26.24%+12.62% 3.97TCr
-0.50%0.00%+20.60%+60.49% 3.26TCr
+0.10%-3.22% - - 1.62TCr
+3.22%-0.88%+30.42%+135.47% 1.67TCr
-0.51%-0.37%+3.42%+29.11% 1.41TCr
+2.35%+3.48%+82.95%+43.41% 1.37TCr
Average +1.55%+0.06%+72.60%+111.64% 2.69TCr
Weighted average by Cap. +1.86%+0.03%+103.01%+153.34%

Financials

2026 *2027 *
Net sales 12.5L 16.95L 14.63L 13.72L 23.5L 16Cr 23.83L 1.61Cr 63.04L 8.12Cr 63.62L 62.24L 27Cr 24L 32.53L 28.09L 26.35L 45.13L 31Cr 45.75L 3.09Cr 1.21Cr 16Cr 1.22Cr 1.2Cr 52Cr
Net income -1.92Cr -2.61Cr -2.25Cr -2.11Cr -3.62Cr -249.3Cr -3.67Cr -25Cr -9.7Cr -124.9Cr -9.79Cr -9.58Cr -415.47Cr -82.37L -1.12Cr -96.4L -90.44L -1.55Cr -106.76Cr -1.57Cr -11Cr -4.15Cr -53Cr -4.19Cr -4.1Cr -177.92Cr
Net Debt 1.04Cr 1.41Cr 1.22Cr 1.14Cr 1.96Cr 135.01Cr 1.99Cr 13Cr 5.25Cr 68Cr 5.3Cr 5.19Cr 225Cr 1.59Cr 2.15Cr 1.86Cr 1.74Cr 2.98Cr 205.75Cr 3.03Cr 20Cr 8.01Cr 103.08Cr 8.08Cr 7.9Cr 342.89Cr
Logo Scancell Holdings plc
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.
Employees
60
Date Price Change Volume
18/26/18 GBX 9.600 +0.63% 6,00,070
17/26/17 GBX 9.540 -0.63% 17,69,094
14/26/14 GBX 9.600 +0.42% 8,86,705
13/26/13 GBX 9.560 -0.42% 13,81,677
12/26/12 GBX 9.600 0.00% 9,92,478
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0954GBP
Average target price
0.2550GBP
Spread / Average Target
+167.30%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCLP Stock